Teitur Trophics, a Danish Biotech company, Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases.
Financing was co-led by Sunstone Life Science Ventures and Sound Bioventures with participation from Innovestor’s Life Science fund, Industrifonden, and P53 Invest.
The proceeds will enable Teitur to progress its lead drug candidate, TT-P34, from candidate selection into clinical development, including a Phase 1b clinical study in neurodegenerative diseases.
In conjunction with the Series A financing, Innovestor’s Milla Koistinaho will join Teitur’s Board of Directors.
Read the full press release.